Systemic Mastocytosis — Structured Data
AI-optimized single page. All data for Systemic Mastocytosis in dense, structured format. Last updated: 2026-03-30.
View interactive disease hub · View all sources
Key Statistics
- Total reported cases
- Unknown
- Mean onset age
- 55 years
- Onset range
- 18–80 years
- Sex ratio (M:F)
- 1:1
- Diagnostic delay
- ~5 years
- Discovered
- 1869 (Nettleship and Tay (cutaneous); Ellis (systemic, 1949))
- Prevalence
- <1/1,000,000
- Classification
- hematologic, mast cell neoplasm
- Pathophysiology
- well understood
- Treatment status
- effective options available
- Genetic basis
- well characterized
- Aliases
- SM, Systemic Mast Cell Disease
Symptoms (14)
| Symptom | Frequency | Severity | Category | Description |
|---|---|---|---|---|
| Urticaria pigmentosa / maculopapular cutaneous mastocytosis | 80% | major | dermatologic | Red-brown macules and papules that urticate on rubbing (positive Darier sign). Present in most ISM patients. Adult-onset urticaria pigmentosa is highly suggestive of systemic disease. |
| Flushing | 60% | major | vascular | Episodic vasodilation causing redness of face, neck, and upper trunk. Triggered by mast cell mediator release (histamine, prostaglandins). Common triggers include heat, exercise, alcohol, and Hymenoptera stings. |
| Pruritus | 55% | major | dermatologic | Generalized itching caused by histamine release from mast cells. Can be severe and significantly impact quality of life. Responds to H1 antihistamines. |
| Anaphylaxis | 49% | cardinal | immunologic | Severe systemic mast cell degranulation causing hypotension, syncope, and potentially death. Hymenoptera venom is the most common trigger. Risk 7.2x higher than general population. All SM patients should carry epinephrine autoinjectors. |
| Abdominal pain | 51% | major | gastrointestinal | The most common GI symptom. Caused by mast cell mediator release and gastric acid hypersecretion. May be crampy or diffuse. |
| Diarrhea | 43% | major | gastrointestinal | Affects 30-50% of patients. Due to gastric acid hypersecretion, malabsorption from mucosal edema, and altered bowel motility caused by mast cell mediators. |
| Fatigue | 80% | major | constitutional | One of the most common and debilitating symptoms, affecting up to 70-90% of patients. Chronic and often underappreciated. Significantly impacts quality of life. |
| Bone pain | 40% | major | musculoskeletal | Musculoskeletal pain particularly affecting the long bones and spine. Associated with osteoporosis and osteolytic/osteosclerotic bone lesions caused by mast cell mediator effects on bone remodeling. |
| Elevated serum tryptase (>20 ng/mL) | 90% | cardinal | laboratory | Basal serum tryptase >20 ng/mL is a minor WHO diagnostic criterion for SM. Correlates with mast cell burden (r=0.8). Median level 67 ng/mL in SM. Must be interpreted in context of hereditary alpha-tryptasemia. |
| Hepatosplenomegaly | 30% | major | organomegaly | Liver and/or spleen enlargement due to mast cell infiltration. More common in advanced subtypes. Splenomegaly is a B-finding; organ dysfunction with ascites or portal hypertension is a C-finding. |
| Nausea and vomiting | 28% | minor | gastrointestinal | Caused by mast cell mediator-driven gastric acid hypersecretion. Responds to H2 antihistamines and proton pump inhibitors. |
| Headache | 30% | minor | neurologic | Vascular headache triggered by histamine-mediated vasodilation. May be episodic, coinciding with other mediator-release symptoms. |
| Cognitive dysfunction / brain fog | 35% | major | neurologic | Neurocognitive symptoms including difficulty concentrating, memory impairment, and mental clouding. Increasingly recognized as a significant contributor to reduced quality of life. |
| Hypotension / presyncope | 25% | cardinal | cardiovascular | Episodic drops in blood pressure caused by histamine-mediated vasodilation and increased vascular permeability during mast cell degranulation. Can progress to anaphylactic shock. |
Molecular Pathway (8 molecules)
| Molecule | Role | Expression change | Evidence level | Targeted by | Explanation |
|---|---|---|---|---|---|
| KIT (CD117) | Central oncogenic driver — mutated receptor tyrosine kinase | Constitutively activated (D816V mutation) | established | Midostaurin, Avapritinib, Imatinib (non-D816V only) | KIT is a transmembrane tyrosine kinase receptor that normally binds SCF to regulate mast cell survival and proliferation. The D816V gain-of-function mutation causes ligand-independent receptor activation, driving all downstream oncogenic signaling. Present in >90% of adult SM cases. |
| SCF (Stem Cell Factor / KIT Ligand) | Normal KIT ligand — bypassed in D816V+ disease | Normal | established | — | SCF normally binds KIT to activate receptor signaling for mast cell growth and survival. In D816V+ SM, the mutant KIT signals constitutively without SCF binding, making the receptor ligand-independent. |
| STAT5 | Key transcription factor in KIT D816V signaling | Constitutively phosphorylated | strong | — | STAT5 is constitutively activated by KIT D816V and localizes to the cytoplasm to form a signaling complex with PI3K. Knockdown of STAT5 inhibits neoplastic mast cell growth. Essential mediator of the STAT5-PI3K-AKT cascade. |
| PI3K | Central kinase in mast cell survival signaling | Constitutively activated | strong | — | PI3K is activated downstream of STAT5 in the KIT D816V signaling cascade. Activates AKT and subsequently mTOR, promoting abnormal mast cell development. BEZ235 (dual PI3K/mTOR blocker) shows growth-inhibitory effects on neoplastic mast cells in preclinical studies. |
| AKT / mTOR | Downstream effectors promoting MC proliferation and survival | Constitutively activated | strong | — | AKT is phosphorylated by PI3K and activates mTOR, completing the STAT5-PI3K-AKT-mTOR cascade. mTORC1 is upregulated in neoplastic mast cells. Rapamycin blocks mTORC1 and inhibits D816V+ MC survival in vitro, though everolimus was ineffective clinically. |
| Tryptase | Key diagnostic biomarker and mast cell mediator | Elevated | established | — | Beta-tryptase is the most abundant mast cell granule protease. Basal serum tryptase >20 ng/mL is a minor WHO diagnostic criterion. Correlates with MC burden (r=0.8). Median 67 ng/mL in SM. Acute rises during degranulation episodes serve as anaphylaxis biomarker. |
| Histamine | Primary vasoactive mediator causing flushing, pruritus, GI symptoms | Elevated (released during degranulation) | established | H1 antihistamines, H2 antihistamines | Histamine is a key preformed mediator stored in mast cell granules. Drives flushing (H1/H2), pruritus (H1), gastric acid hypersecretion (H2), and contributes to anaphylaxis. Targeted by H1 and H2 antihistamines, the first-line therapy for mediator symptoms. |
| NF-kB | Transcription factor driving inflammatory gene expression | Constitutively activated | moderate | — | NF-kB is activated downstream of KIT D816V signaling. Drives expression of inflammatory cytokines, chemokines, and survival factors. Contributes to both mast cell survival and the inflammatory microenvironment. |
Genetic Findings (5)
| Gene | Variant | Type | Frequency in disease | Significance | Also found in |
|---|---|---|---|---|---|
| KIT | D816V (c.2468A>T) | somatic | >90% of adult SM (by sensitive assays) | The central driver mutation of systemic mastocytosis. Causes constitutive ligand-independent activation of the KIT receptor tyrosine kinase, driving mast cell proliferation, survival, and activation. Arises in early hematopoietic stem/progenitor cells. | Gastrointestinal stromal tumors (GIST) (~5% (mostly other KIT mutations)); Core binding factor AML (~25-30%) |
| SRSF2 | Various (most commonly P95H/L/R) | somatic | ~43% of advanced SM | Splicing factor mutation. Strongest individual predictor of inferior survival in advanced SM (HR 5.9). Part of the S/A/R gene panel. | MDS/CMML (~15-50%) |
| ASXL1 | Various truncating mutations | somatic | ~29% of advanced SM | Epigenetic regulator (polycomb group protein). Independently predicts inferior survival (HR 3.4). Part of the S/A/R gene panel. | MDS/MPN/AML (~10-25%) |
| RUNX1 | Various | somatic | ~23% of advanced SM | Transcription factor essential for hematopoiesis. Mutations predict inferior survival (HR 2.4). Part of the S/A/R gene panel. | AML (~10-15%); MDS (~10%) |
| TET2 | Various loss-of-function | somatic | ~47% of advanced SM | Most frequently mutated gene in advanced SM besides KIT. Epigenetic regulator involved in DNA demethylation. Unlike S/A/R mutations, TET2 mutations do not independently predict inferior survival. | MDS/MPN/AML (~10-30%); Clonal hematopoiesis of indeterminate potential (Common) |
Treatment Evidence Matrix (10 treatments)
| Drug | Mechanism | Route | Response rate | Onset | IgM effect | Line | Explanation |
|---|---|---|---|---|---|---|---|
| Avapritinib (Ayvakit) | Selective type 1 KIT D816V inhibitor | Oral 25mg daily (ISM) / 200mg daily (AdvSM) | PIONEER: significant symptom reduction vs placebo; AdvSM: 30% molecular response | Weeks | N/A | 1st | Highly selective inhibitor of KIT D816V with potent activity against the mutant receptor. First and only FDA-approved therapy for ISM (May 2023). In PIONEER trial, avapritinib 25mg daily significantly reduced symptoms (TSS -15.6 vs -9.2, P<0.003) and achieved >=50% tryptase reduction in 54% of patients vs 0% placebo. In AdvSM, achieved molecular responses with KIT D816V becoming undetectable in 30% of patients. |
| Midostaurin (Rydapt) | Multikinase inhibitor (KIT, FLT3, PDGFR, PKC) | Oral 100mg twice daily | 60% ORR in AdvSM; 45% major response | Weeks–months | N/A | 1st | First FDA-approved KIT inhibitor for advanced SM (April 2017). In the landmark phase II trial (NEJM 2016), midostaurin achieved 60% ORR with 45% major responses in 89 evaluable AdvSM patients. Median OS 28.7 months. Active against both wild-type and D816V-mutated KIT. Less selective than avapritinib, with higher rates of GI toxicity. |
| H1 Antihistamines (cetirizine, loratadine, levocetirizine) | H1 receptor antagonist — blocks histamine-mediated skin and vascular symptoms | Oral daily | Variable; mainstay of symptomatic therapy | Hours | N/A | 1st | First-line therapy for mediator-related symptoms. Second-generation (non-sedating) H1 antihistamines are preferred. Reduce flushing, pruritus, and urticaria. Often used in combination with H2 antihistamines for optimal symptom control. Up-dosing (2-4x standard dose) may be needed. |
| H2 Antihistamines (famotidine) | H2 receptor antagonist — blocks histamine-mediated gastric acid secretion | Oral twice daily | Effective for GI symptoms | Hours–days | N/A | 1st | First-line for GI symptoms (abdominal pain, diarrhea, nausea). Inhibit gastric acid secretion via H2 receptors. Combined with H1 antihistamines, they also reduce overall mast cell mediator release. Often supplemented or replaced by proton pump inhibitors for severe GI disease. |
| Cromolyn sodium | Mast cell membrane stabilizer — reduces degranulation | Oral 200mg four times daily (800mg/day) | Moderate for GI symptoms | Weeks (1 month minimum trial) | N/A | 2nd | Mast cell stabilizer that interferes with calcium influx and reduces granule release. Mainly effective for GI symptoms (abdominal pain, diarrhea). Not systemically absorbed, so primarily acts locally in the GI tract. Should be tried for at least one month before judging efficacy. |
| Imatinib (Gleevec) | Tyrosine kinase inhibitor (KIT, BCR-ABL, PDGFR) | Oral 400mg daily | Effective in non-D816V cases; ineffective in D816V+ SM | Weeks–months | N/A | 1st | FDA-approved (2006) for ASM without D816V or unknown KIT status. Inhibits wild-type KIT and select non-codon 816 mutants (e.g., K509I, F522C). D816V causes conformational resistance. Effective in well-differentiated SM (WDSM), which typically lacks D816V. Long-term remissions reported in non-D816V patients. |
| Cladribine (2-CdA) | Purine nucleoside analog — cytoreductive chemotherapy | IV 5mg/m2 daily x5 days, every 4-8 weeks | 50-60% in advanced SM | Weeks–months | N/A | 2nd | Cytoreductive purine analog with significant activity against monocytic lineage cells that share a common progenitor with mast cells. Used in advanced SM when KIT inhibitors are insufficient. Major limitations include myelosuppression and immunosuppression. May be combined with other agents. |
| Omalizumab (Xolair) | Anti-IgE monoclonal antibody | SC monthly injection | Variable; effective for refractory anaphylaxis | Months | N/A | 3rd | Anti-IgE biologic used off-label for SM patients with refractory anaphylaxis despite antihistamines. Reduces IgE-mediated degranulation events. Observational data show significant reduction in anaphylaxis episodes. Small RCTs have not conclusively demonstrated efficacy for all SM symptoms. |
| Epinephrine autoinjector | Adrenergic agonist — emergency anaphylaxis treatment | IM autoinjector (0.3mg) | Life-saving in anaphylaxis | Minutes | N/A | Alternative | All SM patients should carry at least one epinephrine autoinjector. Essential for emergency treatment of anaphylaxis, which occurs at 7.2x the rate of the general population. Reverses vasodilation, bronchospasm, and airway edema. |
| Bisphosphonates / Denosumab | Antiresorptive — inhibit osteoclast-mediated bone resorption | Oral or IV (bisphosphonates) / SC (denosumab) | Effective for osteoporosis management | Months | N/A | 1st | Standard treatment for SM-associated osteoporosis (prevalence 18-37%). Mast cell mediators promote bone resorption, particularly in indolent SM. Bisphosphonates and denosumab reduce fracture risk. DEXA monitoring recommended. |
Diagnostic Criteria
WHO 2001 / Valent Consensus Criteria (2001)
Major criteria (all required)
- Multifocal dense mast cell infiltrates (>=15 mast cells in aggregates) in bone marrow or other extracutaneous organ biopsies
Minor criteria (1+ required)
- >25% of mast cells in bone marrow or other extracutaneous organ biopsy are spindle-shaped or have atypical morphology
- Detection of activating point mutation at codon 816 of KIT in bone marrow, blood, or other extracutaneous organ
- Mast cells in bone marrow, blood, or other extracutaneous organ express CD2 and/or CD25 in addition to normal mast cell markers
- Baseline serum tryptase persistently >20 ng/mL (not valid if associated myeloid neoplasm present)
Diagnosis requires 1 major + 1 minor criterion, or 3 minor criteria. Original criteria adopted by WHO in 2001. Established the framework still used today.
WHO 2022 (5th Edition) Criteria (2022)
Major criteria (all required)
- Multifocal dense mast cell infiltrates (>=15 mast cells in aggregates) in bone marrow or other extracutaneous organ biopsies
Minor criteria (1+ required)
- >25% of mast cells in bone marrow or other extracutaneous organ are spindle-shaped or have atypical/immature morphology
- Detection of KIT activating mutation (D816V or other activating KIT mutation) in bone marrow, blood, or extracutaneous organ
- Mast cells express one or more of CD25, CD2, or CD30 in addition to normal mast cell markers
- Baseline serum tryptase persistently >20 ng/mL (adjusted for hereditary alpha-tryptasemia; not valid if associated myeloid neoplasm)
Diagnosis requires 1 major + 1 minor criterion, or 3 minor criteria. Key updates from 2001: CD30 added as aberrant marker, any activating KIT mutation accepted (not just D816V), hereditary alpha-tryptasemia adjustment recognized, BMM defined as distinct subtype. B-finding updated: KIT D816V VAF >=10% now qualifies.
International Consensus Classification (ICC) 2022 (2022)
Major criteria (all required)
- Multifocal dense mast cell infiltrates (>=15 mast cells in aggregates) in bone marrow or other extracutaneous organ biopsies
Minor criteria (3+ required)
- >25% of mast cells are spindle-shaped or have atypical morphology
- Detection of activating KIT mutation at codon 816
- Mast cells express CD25, CD2, and/or CD30
- Baseline serum tryptase persistently >20 ng/mL
Diagnosis requires the major criterion OR at least 3 minor criteria (differs from WHO which requires major + 1 minor or 3 minor). ICC restricts SM-AHN to myeloid neoplasms only. BMM classified as ISM subvariant rather than distinct subtype.
Differential Diagnoses (7)
| Condition | Key distinction | Shared features |
|---|---|---|
| Mast Cell Activation Syndrome (MCAS) | MCAS has episodic mediator symptoms but does NOT meet full WHO criteria for SM. No multifocal dense MC aggregates. May have 1-2 minor criteria (monoclonal MCAS) or none (idiopathic MCAS). | Flushing, Anaphylaxis, GI symptoms, Elevated acute tryptase during episodes |
| Cutaneous Mastocytosis | Mast cell infiltration limited to the skin. No systemic involvement on bone marrow biopsy. More common in children. Skin lesions may be identical (urticaria pigmentosa). | Urticaria pigmentosa, Positive Darier sign, Pruritus, Flushing |
| Carcinoid Syndrome | Flushing from serotonin-producing neuroendocrine tumor. Elevated 5-HIAA in urine. No mast cell infiltrates. Diarrhea is watery and secretory. | Flushing, Diarrhea, Episodic symptoms |
| Pheochromocytoma | Episodic hypertension (not hypotension). Elevated catecholamines/metanephrines. Adrenal mass on imaging. No skin lesions. | Flushing, Tachycardia, Episodic symptoms |
| Schnitzler Syndrome | Chronic urticarial rash with monoclonal IgM gammopathy. IL-1-driven (not mast cell-driven). Normal tryptase. Responds to anakinra, not antihistamines. Neutrophilic dermal infiltrate on skin biopsy. | Skin lesions, Systemic symptoms, Bone involvement possible, Fever, Elevated inflammatory markers |
| Chronic Spontaneous Urticaria | No fixed pigmented lesions (wheals are transient). Normal tryptase. Responds to antihistamines and omalizumab. No systemic features. | Urticarial lesions, Pruritus |
| Myeloproliferative Neoplasm (MPN) | Primary myeloproliferative neoplasm without mast cell proliferation. JAK2/CALR/MPL mutations. No dense MC aggregates. Note: SM-AHN can co-occur with MPN. | Splenomegaly, Bone marrow abnormalities, Cytopenias possible, Somatic mutations |
Hypotheses (4)
| Hypothesis | Domain | Status | Evidence score | Studies | Evidence for | Evidence against |
|---|---|---|---|---|---|---|
| KIT D816V is necessary and sufficient as the sole driver of indolent SM, while advanced SM requires cooperating mutations in a multi-hit model | pathogenesis | leading | 75/100 | 30 |
|
|
| The STAT5-PI3K-AKT-mTOR axis is the dominant oncogenic signaling cascade downstream of KIT D816V and the primary target for therapeutic intervention | pathogenesis | leading | 70/100 | 20 |
|
|
| Deep molecular responses (KIT D816V undetectable) achieved by selective KIT inhibitors can alter the natural history of SM and prevent progression | treatment | emerging | 50/100 | 8 |
|
|
| Hereditary alpha-tryptasemia (HαT) modifies SM phenotype, increasing mediator symptoms and anaphylaxis risk independent of mast cell burden | genetics | emerging | 40/100 | 6 |
|
|
Open Questions (5)
- Can selective KIT D816V inhibitors prevent progression from indolent to advanced SM?
Avapritinib achieves deep molecular responses in ISM, but whether sustained KIT D816V suppression prevents clonal evolution and disease progression is unknown. Long-term PIONEER follow-up may provide initial answers. - What determines why some patients with KIT D816V develop ISM while others progress to advanced SM?
Nearly all SM subtypes share KIT D816V, yet clinical outcomes range from near-normal survival (ISM) to median 2 months (MCL). The multi-hit model explains some but not all variance. - How can anaphylaxis risk be better predicted and stratified in individual SM patients?
Nearly half of ISM patients experience anaphylaxis, but current risk factors (Hymenoptera sensitization, absence of skin lesions, male sex) have limited predictive power for individual patients. - Can combination therapies targeting KIT D816V plus downstream pathways improve outcomes in multi-mutated advanced SM?
Patients with >=2 S/A/R mutations have median OS of only 2.7 years. Single-agent KIT inhibitors may not overcome the survival advantage conferred by additional oncogenic mutations. - What is the role of the bone marrow microenvironment in supporting neoplastic mast cell survival?
Neoplastic mast cells form dense aggregates in bone marrow, often with associated fibrosis and angiogenesis. The microenvironmental signals sustaining these niches are poorly characterized.
Complications (7)
| Complication | Risk | Timeframe | Description | Monitoring |
|---|---|---|---|---|
| Anaphylaxis | HR 7.2 vs general population; 10-year absolute risk 3.1% | Ongoing lifetime risk | Severe systemic mast cell degranulation causing life-threatening hypotension, bronchospasm, and cardiovascular collapse. Hymenoptera venom is the most common trigger. Risk is highest in ISM without skin involvement. All patients must carry epinephrine autoinjectors. | Allergen sensitization testing (especially Hymenoptera); patient education on triggers; emergency action plan |
| Osteoporosis and pathologic fractures | 18-37% prevalence; vertebral fractures up to 20% | Years | Mast cell mediators promote osteoclastic bone resorption, particularly at the lumbar spine (trabecular bone). Osteoporosis is more common in ISM (38%) than advanced SM (6%), where osteosclerosis may paradoxically increase BMD. Vertebral fractures are the most common complication. | DEXA scan at diagnosis and every 1-2 years; vitamin D and calcium supplementation; bisphosphonates if osteoporosis confirmed |
| Gastrointestinal disease (peptic ulcers, malabsorption) | GI symptoms in 60-80% of patients | Ongoing | Histamine-driven gastric acid hypersecretion can cause peptic ulcers and GI bleeding. Mucosal MC infiltration causes malabsorption and chronic diarrhea. Abdominal pain, nausea, and vomiting are common. GI symptoms are a major source of morbidity in ISM. | Endoscopy if severe symptoms; H2 antihistamines or PPI for acid suppression; nutritional assessment |
| Progression to advanced SM | Low in ISM (<5% lifetime); higher in SSM | Years–decades | ISM may progress to SSM, ASM, SM-AHN, or MCL through acquisition of additional mutations (SRSF2, ASXL1, RUNX1) or clonal evolution. Rising tryptase, increasing KIT D816V VAF, and development of B-findings or C-findings signal progression. | Annual CBC, tryptase, liver function; bone marrow biopsy if clinical deterioration; NGS panel for emerging mutations |
| Cytopenias (anemia, thrombocytopenia, neutropenia) | Primarily in advanced SM (C-findings) | Onset with advanced disease | Bone marrow infiltration by neoplastic mast cells can displace normal hematopoiesis, causing anemia, thrombocytopenia, and neutropenia. These are C-findings that define aggressive SM. Particularly severe in MCL. | Regular CBC monitoring; bone marrow assessment if new cytopenias develop |
| Cardiovascular complications (VTE, stroke) | VTE HR 1.9; stroke HR 1.6 vs general population | Ongoing | SM patients have increased risk of venous thromboembolism and cerebrovascular events. Likely related to chronic inflammatory state and mast cell-mediated vascular effects including heparin release and endothelial activation. | Awareness of VTE/stroke symptoms; standard cardiovascular risk factor management |
| Hepatic dysfunction (ascites, portal hypertension) | Primarily in advanced SM | Onset with advanced disease | Mast cell infiltration of the liver can cause hepatomegaly, portal hypertension, and ascites. Liver dysfunction with elevated alkaline phosphatase and hypoalbuminemia are C-findings defining aggressive SM. | Liver function tests; abdominal imaging for hepatosplenomegaly; albumin levels |
Sources (32)
| Ref | Authors | Title | Journal | Year | Category | Type | Grade | Link |
|---|---|---|---|---|---|---|---|---|
| D2 | Severino MK, Broesby-Olsen S, Vestergaard H, et al. | Prevalence and incidence of mastocytosis in adults: a Danish nationwide register study | BMC Cancer | 2025 | epidemiology | cohort | B | — |
| D1 | Ungerstedt J, Ljung C, Engstrom-Laurent A | Epidemiology of mastocytosis: a population-based study (Sweden) | Acta Oncologica | 2024 | epidemiology | cohort | B | PubMed |
| E2 | Rossini M, Adami S, Zanotti R | Osteoporosis in Systemic Mastocytosis: A Scoping Review | Medicina | 2024 | clinical | systematic review | B | — |
| A4 | Pardanani A | Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management | Am J Hematol | 2023 | reviews | narrative review | A | DOI |
| B6 | Chantran Y, Valent P, Arock M | KIT Mutations and Other Genetic Defects in Mastocytosis | Immunol Allergy Clin North Am | 2023 | genetics | narrative review | B | DOI |
| C4 | Gotlib J, Castells M, Engelbrecht ME, et al. | Avapritinib versus Placebo in Indolent Systemic Mastocytosis | NEJM Evidence | 2023 | treatment | RCT | A | DOI |
| C5 | DeAngelo DJ, Radia DH, George TI, et al. | Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis | Blood | 2022 | treatment | cohort | A | DOI |
| C9 | Castells M, Butterfield J | Treatment of Indolent and Advanced Systemic Mastocytosis | J Allergy Clin Immunol Pract | 2022 | treatment | narrative review | B | DOI |
| A3 | Pardanani A | Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management | Am J Hematol | 2021 | reviews | narrative review | A | DOI |
| A5 | Valent P, Akin C, Hartmann K, et al. | Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal | HemaSphere | 2021 | diagnostics | expert opinion | A | DOI |
| B2 | Chatterjee A, Ghosh J, Bhatt N | Systemic Mastocytosis: Molecular Landscape and Implications for Treatment | Cancers | 2021 | pathophysiology | narrative review | B | DOI |
| C6 | Reiter A, George TI, Engelbrecht ME, et al. | Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial | Nat Med | 2021 | treatment | cohort | A | DOI |
| B4 | Frost MJ, Ferrao PT, Hughes TP, Ashman LK | Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap | Front Pharmacol | 2020 | treatment | narrative review | B | DOI |
| F1 | Valent P | Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts | Theranostics | 2020 | clinical | narrative review | C | DOI |
| B5 | Hoermann G, Gleixner KV, Dinu GE, et al. | Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis | eBioMedicine | 2019 | pathophysiology | basic research | B | DOI |
| E4 | Pardanani A | Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management | Am J Hematol | 2019 | reviews | narrative review | A | DOI |
| C2 | Gotlib J, Reiter A, DeAngelo DJ | FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis | Oncologist | 2018 | treatment | regulatory review | A | DOI |
| C3 | DeAngelo DJ, George TI, Hirshberg B, et al. | Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial | Leukemia | 2018 | treatment | cohort | B | DOI |
| A6 | Valent P, Akin C, Metcalfe DD | Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts | Blood | 2017 | reviews | narrative review | A | DOI |
| A7 | Valent P, Akin C, Hartmann K, et al. | Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future | Cancer Res | 2017 | reviews | narrative review | B | DOI |
| C7 | Akin C, Fumo G, Yavuz AS, et al. | Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations | Haematologica | 2017 | treatment | cohort | B | DOI |
| B1 | Jawhar M, Schwaab J, Schnittger S, et al. | Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis | Leukemia | 2016 | genetics | cohort | B | DOI |
| C1 | Gotlib J, Kluin-Nelemans HC, George TI, et al. | Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis | N Engl J Med | 2016 | treatment | RCT | A | DOI |
| E1 | Lim KH, Tefferi A, Lasho TL, et al. | Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: a nationwide population-based study | Am J Hematol | 2016 | clinical | cohort | B | DOI |
| B7 | Pardanani A, Lasho TL, Finke CM, et al. | ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis | Br J Haematol | 2016 | genetics | cohort | B | DOI |
| D3 | Brockow K | Epidemiology, prognosis, and risk factors in mastocytosis | Immunol Allergy Clin North Am | 2014 | epidemiology | narrative review | B | DOI |
| C8 | Lim KH, Pardanani A, Butterfield JH, et al. | Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis | Blood | 2009 | treatment | cohort | B | DOI |
| E3 | Jensen B, Raithel M, Hahn EG | Gastrointestinal manifestations of systemic mastocytosis | World J Gastroenterol | 2008 | clinical | narrative review | C | — |
| A2 | Valent P, Akin C, Escribano L, et al. | Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria | Eur J Clin Invest | 2007 | diagnostics | expert opinion | A | DOI |
| B3 | Growney JD, Clark JJ, Adelsperger J, et al. | Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade | Blood | 2005 | pathophysiology | basic research | B | DOI |
| D4 | Akin C, Metcalfe DD | Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease | Int Arch Allergy Immunol | 2002 | diagnostics | cohort | B | DOI |
| A1 | Valent P, Horny HP, Escribano L, et al. | Diagnostic criteria and classification of mastocytosis: a consensus proposal | Leuk Res | 2001 | diagnostics | expert opinion | A | DOI |
Pathophysiology Narrative
Systemic mastocytosis is driven by constitutive activation of KIT, a transmembrane tyrosine kinase receptor that normally binds stem cell factor (SCF) to regulate mast cell growth, differentiation, survival, and activation. In >90% of adult SM cases, the somatic gain-of-function mutation KIT D816V causes ligand-independent receptor dimerization and kinase activation.
The mutant KIT triggers multiple downstream signaling cascades: the STAT5-PI3K-AKT-mTOR axis (promoting mast cell survival and proliferation), the RAS-ERK pathway (driving cell growth), and NF-kB activation (promoting inflammatory gene expression). This results in uncontrolled clonal expansion of neoplastic mast cells that accumulate in bone marrow, skin, liver, spleen, and GI tract.
Single-cell analyses have shown that KIT D816V arises in early hematopoietic stem and progenitor cells, with the mutation burden increasing as cells mature into mast cells. In advanced SM, additional somatic mutations in epigenetic regulators (TET2, ASXL1, DNMT3A) and splicing factors (SRSF2) often precede the KIT mutation, creating a multi-mutated stem cell disease.
The clinical manifestations have two distinct mechanisms: (1) tissue infiltration by neoplastic mast cells causing organ damage (C-findings in advanced SM), and (2) inappropriate release of mast cell mediators — histamine, tryptase, heparin, leukotrienes, prostaglandins, and cytokines — causing the characteristic mediator-related symptoms of flushing, pruritus, GI disturbance, anaphylaxis, and osteoporosis.
Genetic Basis Narrative
Systemic mastocytosis is an acquired clonal neoplasm, not an inherited genetic disease. The central molecular driver is the somatic gain-of-function mutation KIT D816V (c.2468A>T), present in >90% of adult cases when detected using highly sensitive assays such as allele-specific quantitative PCR. KIT D816V occurs at the activation loop of the KIT receptor, causing constitutive ligand-independent kinase activity.
In approximately 5% of adult SM cases, other KIT mutations are found (e.g., K509I, F522C, mutations outside exon 17), and in rare cases no KIT mutation is detected (wild-type KIT SM). In children, KIT D816V accounts for only ~25% of KIT mutations; other activating mutations predominate.
In advanced SM, >90% of patients harbor additional mutations beyond KIT D816V. The most frequent are TET2 (~47%), SRSF2 (~43%), ASXL1 (~29%), RUNX1 (~23%), and JAK2 (~16%). The SRSF2/ASXL1/RUNX1 (S/A/R) gene panel has been validated as a prognostic tool — patients with >=2 S/A/R mutations have a median OS of only 2.7 years versus not reached for 0 mutations.
Single-cell analysis has demonstrated that KIT D816V arises in early hematopoietic stem and progenitor cells (HSPCs), with the mutation burden increasing through differentiation. In most advanced SM cases, additional mutations occur prior to KIT D816V, establishing a pre-existing multi-mutated stem cell clone that is then modified by the KIT mutation to produce the mast cell phenotype.